Connor, Clark & Lunn Investment Management (CC&L)
INFI

Connor, Clark & Lunn Investment Management (CC&L)’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-51,580
Closed -$61K – 1479
2022
Q3 		$61K Buy
+51,580
New +$55.6K ﹤0.01% 1062
2020
Q2 		– Sell
-17,685
Closed -$15K – 1208
2020
Q1 		$15K Buy
17,685
+250
+1% +$290 ﹤0.01% 993
2019
Q4 		$17K Sell
17,435
-7,809
-31% -$8.57K ﹤0.01% 907
2019
Q3 		$26K Sell
25,244
-6,925
-22% -$9.44K ﹤0.01% 942
2019
Q2 		$58K Sell
32,169
-13,063
-29% -$21K ﹤0.01% 964
2019
Q1 		$85K Buy
45,232
+15,908
+54% +$23.3K ﹤0.01% 874
2018
Q4 		$35K Sell
29,324
-10,200
-26% -$18.3K ﹤0.01% 925
2018
Q3 		$107K Buy
39,524
+16,800
+74% +$34.8K ﹤0.01% 885
2018
Q2 		$43K Buy
+22,724
New +$45.9K ﹤0.01% 1015
2017
Q3 		– Sell
-625,865
Closed -$983K – 942
2017
Q2 		$983K Sell
625,865
-42,175
-6% -$81.3K 0.01% 502
2017
Q1 		$2.16M Sell
668,040
-49,035
-7% -$121K 0.01% 373
2016
Q4 		$968K Buy
717,075
+22,200
+3% +$29K 0.01% 491
2016
Q3 		$1.08M Buy
694,875
+43,600
+7% +$67K 0.01% 459
2016
Q2 		$866K Buy
651,275
+20,000
+3% +$93.5K 0.01% 494
2016
Q1 		$3.33M Buy
631,275
+45,125
+8% +$276K 0.03% 273
2015
Q4 		$4.6M Buy
586,150
+104,775
+22% +$902K 0.04% 220
2015
Q3 		$4.07M Buy
481,375
+416,975
+647% +$3.85M 0.03% 222
2015
Q2 		$705K Buy
64,400
+15,900
+33% +$204K 0.01% 380
2015
Q1 		$678K Buy
48,500
+7,300
+18% +$112K 0.01% 358
2014
Q4 		$696K Buy
+41,200
New +$600K 0.01% 344

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s INFI Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2022, closing a stake of 51,580 shares — an estimated $61K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in INFI in Q4 2014 and held it in 20 quarters. The position peaked at $4.6M in Q4 2015. 68 funds tracked by Wall St. Rank hold INFI as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 51,580 Infinity Pharmaceuticals, Inc. shares in Q4 2022, an estimated $61K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2014 and held it in 20 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Infinity Pharmaceuticals, Inc. position peaked at $4.6M in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.